Aurobindo Pharma gets US FDA approval for Zidovudine tabs

Aurobindo Pharma Limited, a Rs 2950 crore plus Hyderabad based pharma major, has received the final approval for Zidovudine tablets 60mg (NDA 22-294) and tentative approval for Lamivudine & Zidovudine 30mg / 60mg (NDA 22-296) from the US Food & Drug Administration (US FDA).

Both these new drug applications are for paediatric strengths and are developed based on United Nations initiative to develop paediatric formulations. The products are indicated for the treatment of HIV-1 infection in combination with other anti-retrovirals (ARVs).


Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying